<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04068896</url>
  </required_header>
  <id_info>
    <org_study_id>18-0402</org_study_id>
    <nct_id>NCT04068896</nct_id>
  </id_info>
  <brief_title>Study of NGM120 in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy</brief_title>
  <official_title>A Phase 1a/b Dose-Escalation Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NGM Biopharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NGM Biopharmaceuticals, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study of NGM120 in subjects with advanced solid tumors and pancreatic cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 16, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and Severity of Treatment-Emergent Adverse Events (TEAEs)</measure>
    <time_frame>19 weeks</time_frame>
    <description>The number and percent of patients reporting treatment emergent adverse events (TEAEs) by cohort.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Concentration of NGM120</measure>
    <time_frame>19 weeks</time_frame>
    <description>NGM120 concentration data by cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Anticancer Activity</measure>
    <time_frame>19 weeks</time_frame>
    <description>Assessed using the RECIST Version 1.1 criteria</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Pancreatic Cancer</condition>
  <condition>Metastatic Castration-resistant Prostate Cancer</condition>
  <condition>Bladder Cancer</condition>
  <condition>Melanoma</condition>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Gastric Cancer</condition>
  <condition>Esophageal Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Head Neck Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>NGM120 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NGM120 Subcutaneous Injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NGM120 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NGM120 Subcutaneous Injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NGM120 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NGM120 Subcutaneous Injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NGM120 Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NGM120 Subcutaneous Injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NGM120 Dose 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NGM120 Subcutaneous Injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NGM120 Dose 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NGM120 Subcutaneous Injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NGM120</intervention_name>
    <description>NGM120 Dose 1</description>
    <arm_group_label>NGM120 Dose 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NGM120</intervention_name>
    <description>NGM120 Dose 2</description>
    <arm_group_label>NGM120 Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NGM120</intervention_name>
    <description>NGM120 Dose 3</description>
    <arm_group_label>NGM120 Dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NGM120</intervention_name>
    <description>NGM120 Dose 4</description>
    <arm_group_label>NGM120 Dose 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NGM120</intervention_name>
    <description>NGM120 Dose 5</description>
    <arm_group_label>NGM120 Dose 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NGM120</intervention_name>
    <description>NGM120 Dose 6</description>
    <arm_group_label>NGM120 Dose 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Have histologically confirmed advanced or metastatic castration-resistant prostate
             cancer, bladder cancer, melanoma, non-small cell lung cancer, pancreatic cancer,
             colorectal cancer, gastric cancer, esophageal cancer, ovarian cancer, and head neck
             squamous cell carcinoma.

             Or,

             Have histologically confirmed metastatic pancreatic adenocarcinoma. Recurrent
             unresectable pancreatic cancer is acceptable as long as the treatment is first-line.

          2. Have not received any approved chemotherapy, except in the adjuvant setting.

        Exclusion Criteria:

          1. Subject was using immunosuppressive medications within 14 days before Screening with
             the exception of topical (intranasal, inhaled, and local injection), systemic
             (prednisone equivalent 10 mg/day or less), or as needed for hypersensitivity reactions
             such as computed tomography (CT) scan premedication.

          2. Subject has active infections or other serious underlying significant medical illness,
             abnormal and clinically significant laboratory findings or psychiatric illness/social
             situation.

          3. Subject is using a pacemaker, implantable cardiac defibrillator, neurostimulator,
             cochlear implants, cochlear implants, or other electronic medical equipment.

          4. Subject has documented immunodeficiency or organ transplant.

          5. Subject has an untreated central nervous system disease, leptomeningeal disease or
             cord compression.

          6. Subject has a history, or presence, of significant cardiovascular diseases; including
             uncontrolled hypertension, clinically relevant cardiac arrhythmia, unstable angina or
             myocardial infarction within 6 months before randomization, congestive heart failure &gt;
             New York Heart Association Class II, severe peripheral vascular disease, corrected QT
             (QTc) prolongation &gt;470 msec, clinically significant pericardial effusion.

          7. Subject has a history or presence of documented inflammatory bowel disease.

          8. Subject is known to be positive for human immunodeficiency virus infection.

             -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>NGM Study Director</last_name>
    <role>Study Director</role>
    <affiliation>NGM Biopharmaceuticals, Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rosa Paz</last_name>
    <phone>650-243-5555</phone>
    <email>rpaz@ngmbio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cecilia Tran-Muchowski</last_name>
    <phone>650-243-5555</phone>
    <email>ctranmuchowski@ngmbio.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>NGM Site 122</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90084</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NGM Site 105</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>98517</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NGM Site 108</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>NGM Site 113</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>NGM Site 102</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NGM Site 110</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>NGM Site 117</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>NGM Site 120</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>NGM Site 119</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Lewiston</city>
        <state>Maine</state>
        <zip>04240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NGM Site 106</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NGM Site 103</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NGM Site 115</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NGM Site 111</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>NGM Site 123</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NGM Site 104</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>NGM Site 125</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>NGM Site 124</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>NGM Site 101</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NGM Site 116</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NGM Site 118</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>NGM Site 127</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>NGM Site 107</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>NGM Site 126</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>NGM Site 109</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NGM Clinical Study Site</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NGM Site 112</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>August 22, 2019</study_first_submitted>
  <study_first_submitted_qc>August 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2019</study_first_posted>
  <last_update_submitted>June 29, 2020</last_update_submitted>
  <last_update_submitted_qc>June 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

